Cargando…
Recurrent Hepatocellular Carcinoma in Patient with Crohn's Disease: Incidental or Expected Outcome of Azathioprine?
Hepatocellular carcinoma (HCC) usually occurs in patients with underlying risk factors such as liver cirrhosis and chronic hepatitis B. Although patients with Crohn's disease (CD) are at an increased risk to develop malignancies such as colon cancer, the incidence of HCC in this population is e...
Autores principales: | Botros, Youssef, Mathews, Mary, Patel, Hiren, Shah, Nihar, Baddoura, Walid, de la Torre, Andrew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4691603/ https://www.ncbi.nlm.nih.gov/pubmed/26788381 http://dx.doi.org/10.1155/2015/939136 |
Ejemplares similares
-
Resected Hepatocellular Carcinoma in a Patient with Crohn's Disease on Azathioprine
por: Heron, Valérie, et al.
Publicado: (2016) -
Lymphomatoid granulomatosis associated with azathioprine therapy in Crohn disease
por: Connors, William, et al.
Publicado: (2014) -
An unusual initial presentation of hepatocellular carcinoma as a sellar mass
por: Shah, Nihar, et al.
Publicado: (2015) -
Thalidomide Combined With Azathioprine as Induction and Maintenance Therapy for Azathioprine-Refractory Crohn's Disease Patients
por: Li, Tong, et al.
Publicado: (2020) -
Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease
por: Buisson, Anthony, et al.
Publicado: (2021)